Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.04 USD | +1.17% | +5.04% | -11.57% |
16/05 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
02/05 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.57% | 264M | |
+12.15% | 227B | |
+14.90% | 197B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.53% | 64.15B | |
+16.92% | 53.72B | |
+6.33% | 51.75B | |
+10.93% | 45.2B | |
+5.87% | 37.37B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Earnings Flash (AXGN) AXOGEN Posts Q1 Revenue $41.4M, vs. Street Est of $42.1M